secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0000899923-23-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics secures multi-year UnitedHealthcare contract renewal through 2027
--------------------------------------------------------------------------------

- New agreement covers tests: MyRisk, MyChoice CDx, BRACAnalysis CDx, Foresight, Prequel, GeneSight, Prolaris.
- Contract effective Jan 1, 2024 to Dec 31, 2027; specific pricing terms not disclosed.
- Company reiterates long-term financial targets announced at Sep 19, 2023 investor day, consistent with this renewal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000066/0000899923-23-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992323000066/mygn-20231010.htm
  HTML page:      https://secwatch.observer/filing/0000899923-23-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer